The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.
R. C. Donehower
Research Funding - Incyte
A. Scardina
No relevant relationships to disclose
M. Hill
Employment or Leadership Position - Incyte
J. Bowman
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
R. C. Newton
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
X. Liu
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
P. Scherle
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Q. Wang
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
S. Diamond
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
J. Boer
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
F. Lee
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
T. Gau
Consultant or Advisory Role - ClinTarget
H. A. Burris
No relevant relationships to disclose
J. C. Bendell
No relevant relationships to disclose
S. F. Jones
No relevant relationships to disclose
J. R. Infante
No relevant relationships to disclose